Home
Rune Nielsen's picture
Photo:
Legeforeningen

Rune Nielsen

Associate Professor
  • E-mailRune.Nielsen@uib.no
  • Phone+47 55 97 29 48
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

2011: PhD in epidemiology and health economics of chronic obstructive pulmonary disease (COPD)
2012-2018: Postdoc on the MicroCOPD study working on data collection and bioinformatic analysis on the microbiota of the airways in COPD. 
2018: Associate professor in respiratory medicine, supervision on projects on the microbiome and epidemiology in COPD. 

  • Show author(s) (2024). Lower airway microbiota in COPD and healthy controls. Thorax.
  • Show author(s) (2023). Small airways obstruction and its risk factors in the Burden of Obstructive Lung Disease (BOLD) study: a multinational cross-sectional study. The Lancet Global Health. e69-e82.
  • Show author(s) (2023). Reduced lung function and cause-specific mortality: A population-based study of Norwegian men followed for 26 years. Respiratory Medicine. 9 pages.
  • Show author(s) (2023). Isolated small airways obstruction predicts future chronic airflow obstruction: a multinational longitudinal study. BMJ Open Respiratory Research.
  • Show author(s) (2023). Calcium Channel Blockers and the Risk of Exacerbation in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Study of 48,488 Outpatients. Biomedicines.
  • Show author(s) (2023). Association of respiratory symptoms and lung function with occupation in the multinational Burden of Obstructive Lung Disease (BOLD) study. European Respiratory Journal. 16 pages.
  • Show author(s) (2022). The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis. Microbiome. 11 pages.
  • Show author(s) (2022). The lower airways microbiome and antimicrobial peptides in idiopathic pulmonary fibrosis differ from chronic obstructive pulmonary disease . PLOS ONE.
  • Show author(s) (2022). Period and cohort effects: consequences on spirometric lung function in Norway during the 20th century. European Respiratory Journal Open Research (ERJ Open Research). 1-11.
  • Show author(s) (2022). Factors associated with coronary heart disease in COPD patients and controls. PLOS ONE. 1-17.
  • Show author(s) (2022). ERS statement: A core outcome set for clinical trials evaluating the management of COPD exacerbations. European Respiratory Journal. 19 pages.
  • Show author(s) (2022). A longitudinal study of the pulmonary mycobiome in subjects with and without chronic obstructive pulmonary disease. PLOS ONE. 15 pages.
  • Show author(s) (2021). The pulmonary mycobiome—A study of subjects with and without chronic obstructive pulmonary disease. PLOS ONE. 16 pages.
  • Show author(s) (2021). Respiratory symptoms and respiratory deaths: A multi-cohort study with 45 years observation time. PLOS ONE. 1-14.
  • Show author(s) (2021). Repeated bronchoscopy in health and obstructive lung disease: is the airway microbiome stable? BMC Pulmonary Medicine. 1-12.
  • Show author(s) (2021). Prevalence and Population-Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study. American Journal of Respiratory and Critical Care Medicine. 1353-1365.
  • Show author(s) (2021). Exploring protocol bias in airway microbiome studies: one versus two PCR steps and 16S rRNA gene region V3 V4 versus V4. BMC Genomics. 15 pages.
  • Show author(s) (2021). Chronic airflow obstruction and ambient particulate air pollution. Thorax. 1236-1241.
  • Show author(s) (2021). Bronchodilator response and lung function decline: Associations with exhaled nitric oxide with regard to sex and smoking status. World Allergy Organization Journal. 16 pages.
  • Show author(s) (2020). The airway microbiota and exacerbations of COPD. European Respiratory Journal Open Research (ERJ Open Research). 1-10.
  • Show author(s) (2020). Respiratory symptoms and mortality in four general population cohorts over 45 years. Respiratory Medicine.
  • Show author(s) (2020). Levels of proteinase 3 and neutrophil elastase in plasma, BAL and biopsies in COPD. European Respiratory Journal.
  • Show author(s) (2020). Incremental costs of COPD exacerbations in GOLD stage 2+ COPD in ever-smokers of a general population. Respiratory Medicine: X. 1-7.
  • Show author(s) (2020). Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: The cosaecopd ers task force study protocol. European Respiratory Journal Open Research (ERJ Open Research). 1-10.
  • Show author(s) (2020). Complications and discomfort after research bronchoscopy in the MicroCOPD study. BMJ Open Respiratory Research.
  • Show author(s) (2020). Coagulation markers as predictors for clinical events in COPD. Respirology (Carlton South. Print). 1-10.
  • Show author(s) (2020). Changes in the induced sputum proteome during COPD exacerbations. European Respiratory Journal.
  • Show author(s) (2020). Acute exacerbations of COPD and risk of lung cancer in COPD patients with and without a history of asthma. European Clinical Respiratory Journal. 1-9.
  • Show author(s) (2019). Sputum microbiota and inflammation at stable state and during exacerbations in a cohort of chronic obstructive pulmonary disease (COPD) patients. PLOS ONE. 1-18.
  • Show author(s) (2019). Determinants of fractional exhaled nitric oxide in healthy men and women from the European Community Respiratory Health Survey III. Clinical and Experimental Allergy. 969-979.

More information in national current research information system (CRIStin)